127 related articles for article (PubMed ID: 32764122)
1. Comparison of Interim PET Response to Second-Line Versus First-Line Treatment in Classic Hodgkin Lymphoma: Contribution to the Development of Response Criteria for Relapsed or Progressive Disease.
Kluge R; Wittig T; Georgi TW; Kurch L; Sabri O; Wallace WH; Klekawka T; Fernández-Teijeiro A; Ceppi F; Karlén J; Pears J; Cepelová M; Fosså A; Beishuizen A; Hjalgrim LL; Körholz D; Mauz-Körholz C; Hasenclever D
J Nucl Med; 2021 Mar; 62(3):338-341. PubMed ID: 32764122
[TBL] [Abstract][Full Text] [Related]
2. Only strongly enhanced residual FDG uptake in early response PET (Deauville 5 or qPET ≥ 2) is prognostic in pediatric Hodgkin lymphoma: Results of the GPOH-HD2002 trial.
Kurch L; Hasenclever D; Kluge R; Georgi T; Tchavdarova L; Golombeck M; Sabri O; Eggert A; Brenner W; Sykora KW; Bengel FM; Rossig C; Körholz D; Schäfers M; Feuchtinger T; Bartenstein P; Ammann RA; Krause T; Urban C; Aigner R; Gattenlöhner S; Klapper W; Mauz-Körholz C
Pediatr Blood Cancer; 2019 Mar; 66(3):e27539. PubMed ID: 30426671
[TBL] [Abstract][Full Text] [Related]
3. qPET - a quantitative extension of the Deauville scale to assess response in interim FDG-PET scans in lymphoma.
Hasenclever D; Kurch L; Mauz-Körholz C; Elsner A; Georgi T; Wallace H; Landman-Parker J; Moryl-Bujakowska A; Cepelová M; Karlén J; Álvarez Fernández-Teijeiro A; Attarbaschi A; Fosså A; Pears J; Hraskova A; Bergsträsser E; Beishuizen A; Uyttebroeck A; Schomerus E; Sabri O; Körholz D; Kluge R
Eur J Nucl Med Mol Imaging; 2014 Jul; 41(7):1301-8. PubMed ID: 24604592
[TBL] [Abstract][Full Text] [Related]
4.
Georgi TW; Kluge R; Kurch L; Chavdarova L; Hasenclever D; Stoevesandt D; Pelz T; Landman-Parker J; Wallace WH; Karlen J; Fernández-Teijeiro A; Cepelova M; Fosså A; Balwierz W; Attarbaschi A; Ammann RA; Pears J; Hraskova A; Uyttebroeck A; Beishuizen A; Dieckmann K; Leblanc T; Daw S; Baumann J; Körholz D; Sabri O; Mauz-Körholz C
J Nucl Med; 2018 Oct; 59(10):1524-1530. PubMed ID: 29653979
[TBL] [Abstract][Full Text] [Related]
5. Quantitative assessment of interim PET in Hodgkin lymphoma: An evaluation of the qPET method in adult patients in the RAPID trial.
Georgi TW; Kurch L; Hasenclever D; Warbey VS; Pike L; Radford J; Sabri O; Kluge R; Barrington SF
PLoS One; 2020; 15(4):e0231027. PubMed ID: 32240248
[TBL] [Abstract][Full Text] [Related]
6. Posttreatment PET/CT Rather Than Interim PET/CT Using Deauville Criteria Predicts Outcome in Pediatric Hodgkin Lymphoma: A Prospective Study Comparing PET/CT with Conventional Imaging.
Bakhshi S; Bhethanabhotla S; Kumar R; Agarwal K; Sharma P; Thulkar S; Malhotra A; Dhawan D; Vishnubhatla S
J Nucl Med; 2017 Apr; 58(4):577-583. PubMed ID: 27754902
[TBL] [Abstract][Full Text] [Related]
7. Prediction of outcome in pediatric Hodgkin lymphoma based on interpretation of
Isik EG; Kuyumcu S; Kebudi R; Sanli Y; Karakas Z; Cakir FB; Unal SN
Ann Nucl Med; 2017 Nov; 31(9):660-668. PubMed ID: 28741053
[TBL] [Abstract][Full Text] [Related]
8. Impact of Pretransplantation (18)F-Fluorodeoxyglucose-Positron Emission Tomography on Survival Outcomes after T Cell-Depleted Allogeneic Transplantation for Hodgkin Lymphoma.
Reyal Y; Kayani I; Bloor AJC; Fox CP; Chakraverty R; Sjursen AM; Fielding AK; Ben Taylor M; Bishton MJ; Morris EC; Thomson KJ; Russell N; Mackinnon S; Peggs KS
Biol Blood Marrow Transplant; 2016 Jul; 22(7):1234-1241. PubMed ID: 27095691
[TBL] [Abstract][Full Text] [Related]
9. FDG PET for therapy monitoring in Hodgkin and non-Hodgkin lymphomas.
Barrington SF; Kluge R
Eur J Nucl Med Mol Imaging; 2017 Aug; 44(Suppl 1):97-110. PubMed ID: 28411336
[TBL] [Abstract][Full Text] [Related]
10. Impact of rs12917 MGMT Polymorphism on [
Kewitz-Hempel S; Kurch L; Cepelova M; Volkmer I; Sauerbrey A; Conrad E; Knirsch S; Pöpperl G; Steinbach D; Beer AJ; Kramm CM; Sahlmann CO; Erdlenbruch B; Reinbold WD; Odparlik A; Sabri O; Kluge R; Staege MS
Mol Imaging Biol; 2019 Dec; 21(6):1182-1191. PubMed ID: 30945122
[TBL] [Abstract][Full Text] [Related]
11. Pediatric Hodgkin Lymphoma: Predictive value of interim 18F-FDG PET/CT in therapy response assessment.
Ferrari C; Niccoli Asabella A; Merenda N; Altini C; Fanelli M; Muggeo P; De Leonardis F; Perillo T; Santoro N; Rubini G
Medicine (Baltimore); 2017 Feb; 96(5):e5973. PubMed ID: 28151888
[TBL] [Abstract][Full Text] [Related]
12. Paediatric and adolescent Hodgkin lymphoma: information derived from diffuse organ uptake of 18 F-fluorodeoxyglucose on pre-treatment and on interim PET/CT.
Jorgov L; Montravers F; Balogova S; Ragu C; Pacquement H; Leblanc T; Abbou S; Ducou-Lepointe H; Landman-Parker J; Talbot JN
Eur J Nucl Med Mol Imaging; 2016 Jul; 43(7):1220-30. PubMed ID: 26660144
[TBL] [Abstract][Full Text] [Related]
13. Outcome of Hodgkin Lymphoma Patients With a Posttreatment 18F-Fluoro-2-Deoxy-d-Glucose Positron Emission Tomography (FDG-PET)-Negative Residual Mass: Systematic Review and Meta-analysis.
Adams HJ; Nievelstein RA; Kwee TC
Pediatr Hematol Oncol; 2015; 32(8):515-24. PubMed ID: 26561044
[TBL] [Abstract][Full Text] [Related]
14. Imaging for diagnosis, staging and response assessment of Hodgkin lymphoma and non-Hodgkin lymphoma.
McCarten KM; Nadel HR; Shulkin BL; Cho SY
Pediatr Radiol; 2019 Oct; 49(11):1545-1564. PubMed ID: 31620854
[TBL] [Abstract][Full Text] [Related]
15. Baseline and ongoing PET-derived factors predict detrimental effect or potential utility of 18F-FDG PET/CT (FDG-PET/CT) performed for surveillance in asymptomatic lymphoma patients in first remission.
Morbelli S; Capitanio S; De Carli F; Bongioanni F; De Astis E; Miglino M; Verardi MT; Buschiazzo A; Fiz F; Marini C; Pomposelli E; Sambuceti G
Eur J Nucl Med Mol Imaging; 2016 Feb; 43(2):232-239. PubMed ID: 26283504
[TBL] [Abstract][Full Text] [Related]
16.
Dercle L; Seban RD; Lazarovici J; Schwartz LH; Houot R; Ammari S; Danu A; Edeline V; Marabelle A; Ribrag V; Michot JM
J Nucl Med; 2018 Jan; 59(1):15-24. PubMed ID: 28596157
[TBL] [Abstract][Full Text] [Related]
17. FDG-PET/CT in the management of lymphomas: current status and future directions.
El-Galaly TC; Villa D; Gormsen LC; Baech J; Lo A; Cheah CY
J Intern Med; 2018 Oct; 284(4):358-376. PubMed ID: 29989234
[TBL] [Abstract][Full Text] [Related]
18. The role of FDG-PET in defining prognosis of Hodgkin lymphoma for early-stage disease.
Evens AM; Kostakoglu L
Hematology Am Soc Hematol Educ Program; 2014 Dec; 2014(1):135-43. PubMed ID: 25696846
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of pretransplant FDG-PET in refractory/relapsed Hodgkin lymphoma treated with autologous stem cell transplantation: systematic review and meta-analysis.
Adams HJ; Kwee TC
Ann Hematol; 2016 Apr; 95(5):695-706. PubMed ID: 26931115
[TBL] [Abstract][Full Text] [Related]
20. Interim 18F-FDG PET SUVmax reduction is superior to visual analysis in predicting outcome early in Hodgkin lymphoma patients.
Rossi C; Kanoun S; Berriolo-Riedinger A; Dygai-Cochet I; Humbert O; Legouge C; Chrétien ML; Bastie JN; Brunotte F; Casasnovas RO
J Nucl Med; 2014 Apr; 55(4):569-73. PubMed ID: 24566003
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
